The Pharmaletter

One To Watch

spruce-bio-company

Spruce Biosciences

A late-stage biopharmaceutical company focused on developing novel therapies for rare endocrine disorders with significant unmet medical need.

Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders.

Want to Update your Company's Profile?


More Spruce Biosciences news >